Aldatu’s affordable drug resistance diagnostics matches HIV patients with effective drugs and saves resource-limited healthcare systems money.

Find Out More >>

No thumbnail available

Aldatu Biosciences announces addition of Michael Henry and Marta Fernández Suárez to the Scientific and Business Advisory Board

August 3rd, 2017
Read More >>

In Memory of Mark Wainberg: Aldatu Advisor and HIV Pioneer
April 13th, 2017
Aldatu Biosciences Receives $3 Million SBIR Grant to Expand PANDAA-based HIV Drug Resistance Diagnostic Development
February 7th, 2017
Aldatu Biosciences Secures Impact-Driven Investment as a Public Benefit Corporation
June 3rd, 2016
Aldatu Biosciences Licenses PANDAA Technology from Harvard University
May 18th, 2016

Aldatu Biosciences announces addition of Michael Henry and Marta Fernández Suárez to the Scientific and Business Advisory Board

Aldatu Biosciences announces addition of Michael Henry and Marta Fernández Suárez to the Scientific and Business Advisory Board

August 3rd, 2017

Read More >>

In Memory of Mark Wainberg: Aldatu Advisor and HIV Pioneer
April 13th, 2017
Aldatu Biosciences Receives $3 Million SBIR Grant to Expand PANDAA-based HIV Drug Resistance Diagnostic Development
February 7th, 2017
Aldatu Biosciences Secures Impact-Driven Investment as a Public Benefit Corporation
June 3rd, 2016
Aldatu Biosciences Licenses PANDAA Technology from Harvard University
May 18th, 2016